Month: October 2025
02
Oct
2025
AAVantgarde Bio receives ODD and CTA for AAVB-039 to address Stargardt Disease
- AAVB-039 addresses the root cause of the disease, benefitting patients with any ABCA4 mutation
- AAVB-039 is currently being assessed in the CELESTE interventional clinical trial and we continue recruiting in our STELLA observational study
Please click here to read more